A Phase 1 interventional study of Fluticasone Propionate and Placebo for Fluticasone Propionate in Pulmonary Disease, Chronic Obstructive, sponsored by Pfizer. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-13.
Sponsored by Pfizer · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 4 under way, 1 of them phase 3. Fluticasone · Pulmonary Disease, Chronic Obstructive.
Among the 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive, this one is the 53rd largest by enrollment, is one of 5 that started in 2011, is one of 11 in phase 1, and was the 26th registered.
5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →3 of the 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive are open now, in 3 countries. Recruiting first, the newest first:
Western University, Canada · Sites in Canada
Ages 50–85
National Institute of Respiratory Diseases, Mexico · Sites in Mexico
Ages 35–85 · Women only
Eurofarma Laboratorios S.A. · Sites in Brazil
Ages 40+
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 62 across 3,845 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 95 across the 59 interventional studies. Of the 48 that completed or were terminated, 24 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 59 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
22 studies in Pulmonary Disease, Chronic Obstructive by Pfizer: 2 open now, 2 under way, 2 of them phase 3. Of 19 finished, 5 (26%) have results posted.
Among the 22 studies in Pulmonary Disease, Chronic Obstructive by Pfizer, this one is the 17th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2011, is one of 5 in phase 1, and was the 15th registered.
Pfizer’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2003.
1 of the studies testing fluticasone in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07192016Western University, Canada129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 22 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
Study to assess effect of Fluticasone Propionate on acute lung inflammation following inhaled lipopolysaccharide (LPS) challenge. Study will be conducted in healthy volunteers. Assessment of inflammation will be via sputum induction.
Methodology Validation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Fluticasone Propionate
Drug: Placebo for Fluticasone Propionate
Dry powder for inhalation, Single Dose, 500mcg
Dry powder for inhalation, Single Dose, placebo
Sputum Neutrophil (%)
Time frame: 6 hours post LPS challenge
Sputum Inflammatory cytokines (IL-6, MCP-1 and MIP1beta)
Time frame: 6 hours post LPS challenge
Blood Inflammatory Cytokines (IL-6, MCP-1, fibrinogen, CC16, CRP and MIP1beta)
Time frame: 1, 4 and 6 hours post LPS challenge
Sputum cells (macrophages and total cell count)
Time frame: 6 hours post LPS challenge
The record gives a start of Jul 2011, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone
Pulmonary Disease, Chronic Obstructive →